CorMedix Inc. Form 4 November 14, 2013

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: Estimated average

OMB

Number:

burden hours per response...

**OMB APPROVAL** 

3235-0287

2005

0.5

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Lefkowitz Steven W

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

CorMedix Inc. [CRMD]

(Check all applicable)

(Last)

(City)

(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

\_X\_\_ Director 10% Owner Other (specify X\_ Officer (give title

C/O CORMEDIX INC., 745 ROUTE 11/13/2013

202-206, SUITE 303

below)

Interim Chief Financial Ofcr

(Street) 4. If Amendment, Date Original

(Zip)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

10,000

I

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

BRIDGEWATER, NJ US 08807

(State)

							1,	, , , , , , , , , , , , , , , , , , , ,	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securiti or(A) or Dis (Instr. 3, 4	posed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.001 par value per share	11/13/2013		Code V	Amount 42,857	(D)	Price \$ 0.35	, , , , , , , , , , , , , , , , , , ,	D	
Common Stock, \$0.001 par value per share							100,000 (8)	I (1)	Wade Capital Corporation Money Purchase Plan

1

## Edgar Filing: CorMedix Inc. - Form 4

Common Stock,	Reporting Person's
\$0.001 par	Wife
value per	
share	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control

(9-02)

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour Number Shares
Warrant (right to purchase Common Stock)	\$ 3.4375					08/20/2013	03/24/2015	Common Stock, \$0.001 par value per share	5,00
Stock Option (right to buy)	\$ 0.9					(2)	03/20/2023	Common Stock, \$0.001 par value per share	120,0
Stock Option (right to buy)	\$ 0.68					<u>(3)</u>	12/05/2022	Common Stock, \$0.001 par value per share	150,0
Senior Convertible Note (convertible into Common Stock)	\$ 0.35	11/13/2013		С	42,857	11/13/2012	11/13/2013	Common Stock, \$0.001 par value per share	42,8
,	\$ 0.4					11/13/2012	11/13/2017		37,5

## Edgar Filing: CorMedix Inc. - Form 4

Warrant (right to purchase Common Stock)				Common Stock, \$0.001 par value per share	
Warrant (right to purchase Common Stock)	\$ 0.4	09/20/2012	09/20/2017	Common Stock, \$0.001 par value per share	87,5
Stock Option (right to buy)	\$ 0.29	<u>(4)</u>	01/06/2022	Common Stock, \$0.001 par value per share	30,0
Stock Option (right to buy)	\$ 1.1	<u>(5)</u>	08/11/2021	Common Stock, \$0.001 par value per share	30,0
Warrant (6)	\$ 3.4375	<u>(7)</u>	03/24/2015	Common Stock, \$0.001 par value per share	19,5

## **Reporting Owners**

Reporting Owner Name / Address	Keiauonsnips						
- 0	Director	10% Owner	Officer	Other			
Lefkowitz Steven W							
C/O CORMEDIX INC.	X		Interim Chief Financial Ofcr				
745 ROUTE 202-206, SUITE 303	Λ		internii Cinei Financiai Ofci				
BRIDGEWATER, NJ US 08807							

# **Signatures**

Alexander M. Donalson by Power of Attorney 11/14/2013

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).

Reporting Owners 3

#### Edgar Filing: CorMedix Inc. - Form 4

- (2) These options vest quarterly over two years beginning June 13, 2013.
- (3) These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- (4) The options vest in full on the first anniversary of the date of grant.
- (5) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- (6) (Right to buy Common Stock, \$0.001 par value per share)
- (7) The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.
- (8) The reporting person's Form 4 filed September 23, 2013 mistakenly indicated the total number of securities beneficially owned was 181,072, when in fact the total number of securities beneficially owned is 100,000.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.